IOVANCE BIOTHERAPEUTICS, INC.

Iovance Biotherapeutics updated its corporate presentation, highlighting strong financial performance and significant pipeline progress. The company reported 2Q26 revenue of approximately $99 million, exceeding its guidance by over 10%, and achieved a 56% gross margin from cost of sales. With a cash position of $304 million, Iovance projects a cash runway into the second half of 2028. The presentation also detailed advancements in its TIL therapy pipeline, including positive clinical data for lifileucel in NSCLC and soft tissue sarcomas, and ongoing global expansion with over 95 treatment centers.

Iovance Biotherapeutics reported a significant increase in product revenue for Q2 2026, reaching $99.3 million, a 66% rise year-over-year. The company also substantially narrowed its net loss to $47.3 million, or $0.11 per share, compared to $111.7 million, or $0.33 per share, in the prior year. Regulatory progress for Amtagvi® continues with marketing authorization in Australia and resubmission in the UK, alongside ongoing clinical trials for pipeline candidates. The company believes it has sufficient capital to fund operations for at least the next twelve months.

Iovance Biotherapeutics reported record second quarter 2026 financial results, with total product revenue reaching ~$99.3 million, a 66% increase year-over-year. The company achieved a gross margin of 56% and significantly reduced its net loss to $(47.3) million, or $(0.11) per share. Due to strong performance, Iovance is reviewing its full-year 2026 revenue guidance and announced key clinical and regulatory advancements, including FDA Fast Track Designation for Lifileucel in soft tissue sarcomas and Amtagvi approval in Australia.

Iovance Biotherapeutics, Inc. announced it will host a conference call and live audio webcast to report its second quarter 2026 financial results and corporate updates. The event is scheduled for Thursday, August 6, 2026, at 8:30 a.m. ET. Interested parties can register for the live or archived webcast through the provided link or the company's investor relations website.

Iovance Biotherapeutics updated its corporate presentation on June 30, 2026, for use at healthcare conferences and with analysts and stockholders. The presentation provides a corporate overview, including financial guidance for Q2 2026 revenue of $86M-$88M and full-year 2026 revenue of $350M-$370M. It also highlights the commercial launch of Amtagvi, pipeline advancements, and manufacturing capabilities, projecting a cash runway into 2028.

Iovance Biotherapeutics, Inc. announced the grant of inducement stock options covering an aggregate of 140,860 shares of its common stock to twenty-seven new, non-executive employees. The awards were granted on June 18, 2026, under the company's Amended and Restated 2021 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $3.91, which was the closing price on the grant date, and vests over a three-year period.

Iovance Biotherapeutics announced that Australia's Therapeutic Goods Administration (TGA) granted conditional approval for Amtagvi (lifileucel) for previously treated advanced melanoma. This marks the company's third marketing authorization for Amtagvi and represents the first T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy. The approval is significant given Australia's high melanoma rates and was based on positive safety and efficacy data from the C-144-01 clinical trial.

Iovance Biotherapeutics received U.S. FDA allowance for its Investigational New Drug (IND) application for IOV-5001, a next-generation interleukin-12 (IL-12) tethered TIL therapy. The company plans to initiate a Phase 1/2 basket trial in the second half of 2026, targeting advanced colorectal, triple-negative, and estrogen receptor-low breast cancers, as well as other highly prevalent solid tumors responsible for over 100,000 U.S. deaths annually. IOV-5001 is engineered to enhance efficacy in immunologically 'cold' tumors and improve safety by localizing IL-12 activity within the tumor, building on prior therapy that showed a 63% objective response rate.

Iovance Biotherapeutics, Inc. announced the grant of inducement stock options for an aggregate of 93,340 shares of its common stock to thirteen new, non-executive employees on May 21, 2026. These awards were issued under the company's Amended and Restated 2021 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $3.70, matching the closing price on the grant date, and vests over a three-year period, subject to continued employment.

Iovance Biotherapeutics, Inc. announced that its Interim CEO, President and General Counsel, Fred Vogt, and Chief Financial Officer, Corleen Roche, will participate in a fireside chat. The event is part of the 2026 Jefferies Global Healthcare Conference, scheduled for June 4, 2026, at 1:25 p.m. ET in New York, NY. A webcast of the presentation will be available on the company's investor relations website.